Minimally invasive surgery for advanced stomach cancer after chemoimmunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stomach or gastroesophageal junction cancer that is mostly adenocarcinoma (a common type).
- Your cancer has spread only to lymph nodes near the main blood vessels (para-aortic area) and no other distant organs.
- You have not had previous treatment for this cancer, or if you had chemotherapy, it ended more than 6 months ago and your cancer came back.
- You are healthy enough for surgery, with good heart, lung, liver, kidney, and blood function.
- You have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
This trial studies whether a minimally invasive (laparoscopic) removal of the entire stomach, along with lymph node removal, can be done safely and effectively for certain stomach cancers. It may be an option if your cancer is in the stomach, has limited spread to nearby lymph nodes, and can be fully removed.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.